PHASE-II STUDY OF CHLOROZOTOCIN IN LEUKEMIA AND OTHER HEMATOLOGIC MALIGNANCIES

Chlorozotocin is a glucose-containing chloroethylnitrosourea that is relatively nonmyelosuppressive at doses that produce significant antileukemic activity in L1210 murine leukemia. The present phase II trial tested chlorozotocin using the nonmyelosuppressive 120-mg/m2 dose in leukemia and lymphoma patients. This dose was given weekly or daily for 3 days to the leukemia patients and every 6 wk to the lymphoma patients. Chlorozotocin was not effective in heavily pretreated leukemia and lymphoma patients but gave evidence of activity, particularly in Hodgkin''s disease, that might be exploited in a less heavily treated population.